Zacks Investment Research on MSN
ZBIO tanks despite positive data from rare autoimmune diseases study
Zenas BioPharma ZBIO announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for treating patients with immunoglobulin G4-related disease (IgG4-RD), has met ...
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma First data from Phase 1 trial show the safety and tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results